

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 AUG 10 Time limit for inactive STN sessions doubles to 40  
minutes  
NEWS 3 AUG 18 COMPENDEX indexing changed for the Corporate Source  
(CS) field  
NEWS 4 AUG 24 ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced  
NEWS 5 AUG 24 CA/CAPLUS enhanced with legal status information for  
U.S. patents  
NEWS 6 SEP 09 50 Millionth Unique Chemical Substance Recorded in  
CAS REGISTRY  
NEWS 7 SEP 11 WPIDS, WPINDEX, and WPIX now include Japanese FTERM  
thesaurus  
NEWS 8 OCT 21 Derwent World Patents Index Coverage of Indian and  
Taiwanese Content Expanded  
NEWS 9 OCT 21 Derwent World Patents Index enhanced with human  
translated claims for Chinese Applications and  
Utility Models  
NEWS 10 NOV 23 Addition of SCAN format to selected STN databases  
NEWS 11 NOV 23 Annual Reload of IFI Databases  
NEWS 12 DEC 01 FRFULL Content and Search Enhancements  
NEWS 13 DEC 01 DGENE, USGENE, and PCTGEN: new percent identity  
feature for sorting BLAST answer sets  
NEWS 14 DEC 02 Derwent World Patent Index: Japanese FI-TERM  
thesaurus added  
NEWS 15 DEC 02 PCTGEN enhanced with patent family and legal status  
display data from INPADOCDB  
NEWS 16 DEC 02 USGENE: Enhanced coverage of bibliographic and  
sequence information

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,  
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN customer  
agreement. This agreement limits use to scientific research. Use  
for software development or design, implementation of commercial  
gateways, or use of CAS and STN data in the building of commercial  
products is prohibited and may result in loss of user privileges  
and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 13:27:14 ON 18 DEC 2009

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'REGISTRY' ENTERED AT 13:27:32 ON 18 DEC 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 DEC 2009 HIGHEST RN 1197964-91-2

DICTIONARY FILE UPDATES: 16 DEC 2009 HIGHEST RN 1197964-91-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10576761.str



```

chain nodes :
18 19 32 33 34
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 22 23 24 25 26 27 28 29
30
chain bonds :
11-18 18-19 29-32 30-33 33-34
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-11 7-8 8-9 9-10 9-12 10-11 10-15 12-13
13-14 14-15 22-23 22-27 22-28 23-24 23-30 24-25 25-26 26-27 28-29 29-30
exact/norm bonds :
5-7 6-11 7-8 8-9 10-11 11-18 18-19 22-23 22-27 22-28 23-24 23-30 24-25
25-26 26-27 28-29 29-30 29-32 30-33 33-34
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-12 10-15 12-13 13-14 14-15
isolated ring systems :
containing 1 :

```

G1:C,O

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS  
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 18:CLASS 19:CLASS  
22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS  
30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using SIN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 13:28:05 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 685 TO ITERATE

100.0% PROCESSED 685 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 12130 TO 15270

PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 13:28:09 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 14347 TO ITERATE

100.0% PROCESSED 14347 ITERATIONS

42 ANSWERS

SEARCH TIME: 00.00.01

L3 42 SEA SSS FUL L1

=> s l3 and caplus/lc

69514057 CAPLUS/LC


L4 37 L3 AND CAPLUS/LC

=> s l3 not l4

L5 5 L3 NOT L4

=> d l5 1-5


L5 ANWEX 1 OF 5 REGISTRY COPYRIGHT 2009 ACS on STM  
 RN 1027502-97-9 REGISTRY  
 ED Entered STM: 12-Jun-2009  
 CN 2R-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenz[a,d]cyclohept-en-3-ylidene)methyl]-3,3-dihydro-1-[2-[1-piperazinyl]ethyl]- (CA INDEX NAME)  
 MF C28 H28 F2 N4 O  
 SS Other Sources  
 Database: ChemSpider (ChemCo, Inc.)



\*\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*\*

L5 ANWEX 3 OF 5 REGISTRY COPYRIGHT 2009 ACS on STM  
 RN 1027448-35-6 REGISTRY  
 ED Entered STM: 10-Jun-2009  
 CN 2R-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6R)-ylidene)methyl]-1,2-dihydro-1-[2-[1-piperazinyl]ethyl]- (CA INDEX NAME)  
 FE STEREOBOND  
 MF C28 H26 F2 N4 O2  
 SS Other Sources  
 Database: ChemSpider (ChemCo, Inc.)


Double bond geometry as shown.



\*\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*\*

L5 ANWEX 2 OF 5 REGISTRY COPYRIGHT 2009 ACS on STM  
 RN 1027155-70-9 REGISTRY  
 ED Entered STM: 13-Jun-2009  
 CN 2R-Benzimidazol-2-one, 6-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6R)-ylidene)methyl]-3,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)  
 FE STEREOBOND  
 MF C28 H25 F2 N3 O3  
 SS Other Sources  
 Database: ChemSpider (ChemCo, Inc.)


Double bond geometry as shown.



\*\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*\*

L5 ANWEX 4 OF 5 REGISTRY COPYRIGHT 2009 ACS on STM  
 RN 1026946-78-0 REGISTRY  
 ED Entered STM: 10-Jun-2009  
 CN 2R-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6R)-ylidene)methyl]-1-[2-[(2R,6S)-2,6-dimethyl-4-morpholinyl]ethyl]-1,7-dihydro-, xal- (CA INDEX NAME)  
 FE STEREOBOND  
 MF C29 H29 F2 N3 O3  
 SS Other Sources  
 Database: ChemSpider (ChemCo, Inc.)


Relative stereochemistry.  
 Double bond geometry as shown.



\*\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*\*

L5 ADDENDUM 5 OF 5 REGISTRY COPYRIGHT 2009 ACS on STN  
 M0 1016047-11-9 REGISTRY  
 E0 Entered STN 06-Jun-2009  
 C0 2R-Benzimidazol-2-one, 5-[(1R)-1-(3,8-difluorodibenz[b,e]oxepin-11(6R))-  
 ylidene)methyl]-2,2-dihydro-2-(1R)-2-methyl-2-(1-piperazinyl)methyl)-  
 [CA  
 INDEX NAME:  
 PS STEREOBOND  
 M0 C19 H28 F2 N4 O2  
 S0 Other Sources  
 Database: ChemSpider (ChemCo, Inc.)

Absolute stereochemistry.  
 Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

=> fil caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	201.96	202.18

FILE 'CAPLUS' ENTERED AT 13:28:40 ON 18 DEC 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Dec 2009 VOL 151 ISS 26  
FILE LAST UPDATED: 17 Dec 2009 (20091217/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009  
USTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2009

CAPlus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 13:27:14 ON 18 DEC 2009)

FILE 'REGISTRY' ENTERED AT 13:27:32 ON 18 DEC 2009

L1	STRUCTURE UPLOADED
L2	1 S L1
L3	42 S L1 FULL
L4	37 S L3 AND CAPLUS/LC
L5	5 S L3 NOT L4

FILE 'CAPLUS' ENTERED AT 13:28:40 ON 18 DEC 2009

=> s l4	
L6	2 L4

=> d ibib abs hitstr 1-  
YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):n

=> d ibib abs hitstr 1-2






[illegible]

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LENS DISPLAY FORMAT  
OTHER SOURCE(S): CASREACT 143:153374; MARPAT 143:153374  
OI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


A8 Title compds. 1 [Y = CR<sub>2</sub>, O; K1-2 = H, F; K3 = 2-amino, 2-heterocycloyl; 2 = divalent alkyl; with some specific exceptions] are prepared for instance.

16 ANSWER 1 OF 2 CHEM34 COPYRIGHT 2009 ACS on STM (Continued)




IN 860009-99-0 CAPLUS  
 CN 2E-Benzimidazol-2-one, 1-[2-(dimethylamino)ethyl]-5-[(E)-(3-fluorodibenz[b,e]oxepin-11(8H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



200 860010-00-0 CAPLUS  
C01 28-Benzimidazol-2-one, 5-[ (E) - (3-fluorobenz[b,c]oxepin-11 (6H) -  
ylidene)methyl]-1,3-dihydro-1-[3-(4-methyl-1-piperazinyl)propyl]- (CA  
INDEX NAME)

Double bond geometry as shown



16 ANNEAL 1 OF 2 CAPSULE CRYSTALLIZATION 49% MCS ON STN (Continued)


It is prep'd from (E)-1(1-bromomethyl)-2-(3-fluoro-6,11-dihydrobenzo[5,6-b]indol-2-yl)-1,1,2-dimethyl-2-(morpholin-4-yl)ethyl)-5,4,4,5,4,5-tetramethyl-3,7,7,8,8,8-hexafluoro-2,3,7,8-tetrahydro-1,4-benzoxazolo[4,3-g]-1,2,4-triazole-6-one (prep. given) with  $\text{NaHCO}_3$  in  $\text{CH}_2\text{Cl}_2$  at  $0^\circ\text{C}$  for 1 hr. The  $\text{K}_d$  is 500 nM for the mineralocorticoid receptor and  $\text{K}_i$   $\times$  3,000 nM for the glucocorticoid receptor. 1 are useful for the treatment of congestive heart failure, hypertension, and/or edema.

17

71304-06-2P	860009-94-5P	860009-99-0P
860010-13-7P	860010-13-5P	860010-13-6P
860010-04-4P	860010-06-6P	860010-07-0P
860010-12-4P	860010-12-5P	860010-14-4P
860010-13-7P	860010-13-5P	860010-13-6P
860010-19-1P	860010-21-5P	860010-16-0P
860010-15-8P	860010-16-4P	860010-40-0P
860010-42-0P	860010-44-2P	860010-44-3P
860010-46-4P	860010-56-4P	860010-55-5P

KL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BGL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of benznidazole-substituted tricyclic steroid hormone nuclear receptor modulators)

FN 710344-06-2 CAPLOS  
 CN 2H-Benzimidazol-2-one, 5-[12,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)nethyl]-1,3-dihydro-1-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)




HN 060009-94-5 CAPLUS  
 CN 2H-Benzimidazol-2-one, 1-[1,1-dimethyl-2-(4-morpholinyl)ethyl]-5-[(E)-[3-  
 Fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX  
 NAME)

Double bond geometry as shown.

1.6 ANSWER 1 OF 2 CHAPTER COPYRIGHT 2009 MCS on STM (Continued)


DE 860010-01-1 CAPLUS  
FN 860010-01-1 CAPLUS  
CN 2H-Benzimidazol-2-one, 5-[4-(E)-(3-fluorodibenz[b,e]oxepan-11(6H)-ylidene)methyl]-1,3-dihydro-3-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.




RXN 060010-03-3 CAPLOS  
 CN 2H-Benzimidazole-2-one, 5-[(E)-[3-fluorodibenz[b,e]oxepan-11(6H)-  
 ylidene)methyl]-3,3-dihydro-1-[(3E)-1-methyl-2-(4-morpholinyl)ethyl]-  
 (CA  
 INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




CN 2H-benzimidazol-2-one, 5-[(E)-[3-fluorodibenz[b,e]oxepin-11 (6H)-  
 ylidene)methyl]-1,3-dihydro-1-[(1S)-1-methyl-2-(4-morpholinyl)ethyl]-  
 (1R)

Absolute stereochemistry.




HN 96010-06-6 CAPLUS  
CN 28-Benzimidazol-2-one, 1-[2-[(1R,6R)-2,6-dimethyl-4-morpholinylethyl]-5-[(E)-13-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-, rel- (CA INDEX NAME)

Relative stereochemistry.  
Double bond geometry as shown.




HN 96010-01-7 CAPLUS  
CN 28-Benzimidazol-2-one, 5-[(E)-13-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(1-piperazinylethyl)- (CA INDEX NAME)

Double bond geometry as shown.




HN 96010-14-6 CAPLUS  
CN 28-Benzimidazol-2-one, 5-[(E)-13,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinylethyl)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




HN 96010-15-7 CAPLUS  
CN 28-Benzimidazol-2-one, 5-[(E)-13,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(1-dimethyl-4-morpholinylethyl)-1,3-dihydro-, rel- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




HN 96010-12-4 CAPLUS  
CN 28-Benzimidazol-2-one, 5-[(E)-13,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-methyl-1-piperazinylethyl)- (CA INDEX NAME)

Double bond geometry as shown.




HN 96010-13-5 CAPLUS  
CN 28-Benzimidazol-2-one, 5-[(E)-13,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(1-pyrrolidinylethyl)- (CA INDEX NAME)

Double bond geometry as shown.




HN 96010-16-8 CAPLUS  
CN 28-Benzimidazol-2-one, 5-[(E)-13,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinylethyl)-1,3-dihydro-, rel- (CA INDEX NAME)

Double bond geometry as shown.




HN 96010-17-9 CAPLUS  
CN 28-Benzimidazol-2-one, 5-[(E)-13,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(1-dimethyl-4-morpholinylethyl)-1,3-dihydro-, rel- (CA INDEX NAME)

Relative stereochemistry.  
Double bond geometry as shown.




HN 860010-19-3 CAPLUS  
CN 28-Benzimidazol-2-one, 5-[(E)-(3,7-difluorobenz[e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)propyl]- (CA INDEX NAME)

Double bond geometry as shown.




HN 860010-21-5 CAPLUS  
CN 28-Benzimidazol-2-one, 5-[(E)-(3,7-difluorobenz[e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.




HN 860010-39-4 CAPLUS  
CN 28-Benzimidazol-2-one, 5-[(E)-(3,7-difluorobenz[e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




HN 860010-40-8 CAPLUS  
CN 28-Benzimidazol-2-one, 5-[(E)-(3,7-difluorobenz[e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




HN 860010-39-6 CAPLUS  
CN 28-Benzimidazol-2-one, 5-[(E)-(3,7-difluorobenz[e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.




HN 860010-32-8 CAPLUS  
CN 28-Benzimidazol-2-one, 5-[(E)-(3,7-difluorobenz[e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.



HN 860010-42-0 CAPLUS  
CN 28-Benzimidazol-2-one, 5-[(E)-(3,7-difluorobenz[e]oxepin-11(6H)-ylidene)methyl]-1-[1,1-dimethyl-2-(4-morpholinyl)ethyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.




HN 860010-44-2 CAPLUS  
CN 28-Benzimidazol-2-one, 5-[(E)-(3,7-difluorobenz[e]oxepin-11(6H)-ylidene)methyl]-2-[2-[(2S,6S)-2,6-dimethyl-4-morpholinyl]ethyl]-1,3-dihydro- (CA INDEX NAME)

Relative stereochemistry.  
Double bond geometry as shown.




ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LEXIS DISPLAY FORMAT  
OTHER SOURCE(S): MARPAT 11/17/90  
C2




As dibenzosuberone derivative, such as I [X = CH<sub>2</sub>, E = H, Cl, Br, I, CN, halogen, alkyl, silyloxy, amino, etc.], R2 = aryl, heteroaryl, R3 = H, alkyl, and heterocyclic analogs thereof, such as I [X = O, S, NH, NMe, etc.], were prepared for therapeutic use in the treatment of psoriasis, disorders susceptible to steroid hormone nuclear receptor modulation.

compd. are claimed for use the treatment of disorders, such as Conn's Syndrome, primary and secondary hyperaldosteronism, increased sodium retention, increased natriuresis and potassium excretion (diuretic), increased water retention, hypertension (isolated systolic and combined systolic/diastolic), arrhythmias, myocardial infarction, myocardial infarction, Brugada's Syndrome, disorders associated with arrhythmias, myocardial infarction, diabetes mellitus, osteoporosis, polyuria, polydipsia, inflammation, rheumatoid arthritis, asthma, or chronic obstructive pulmonary disease, Diastolic or systolic congestive heart failure, autoimmune disorders, tissue rejection associated with organ transplant, malignancies such as leukemias and lymphomas, acute adrenal insufficiency, noncystic adrenal hyperplasia, rheumatic fever, polyarthritis nodosa, granulomatous polyarthritis, inhibition of myeloid cell lines, disease proliferation/apoptosis, HIV viral suppression and regulation, hypercalcemia, modulation of the Th1/Th2 cytokine balance,


peripheral vascular disease, diabetic nephropathy, cirrhosis with edema and ascites, esophageal varices, Addison's Disease, muscle weakness, increased melanin pigmentation of the skin, weight loss, hypotension, hypoglycemia, Cushing's Syndrome, obesity, hypertension, glucose intolerance, hyperlipidemia, diabetes mellitus, osteoporosis, polyuria, polydipsia, inflammation, rheumatoid arthritis, asthma, or chronic obstructive pulmonary disease, Diastolic or systolic congestive heart failure, autoimmune disorders, tissue rejection associated with organ transplant, malignancies such as leukemias and lymphomas, acute adrenal insufficiency, noncystic adrenal hyperplasia, rheumatic fever, polyarthritis nodosa, granulomatous polyarthritis, inhibition of myeloid cell lines, disease proliferation/apoptosis, HIV viral suppression and regulation, hypercalcemia, modulation of the Th1/Th2 cytokine balance,



71-9 CAPLUS  
28-Benzimidazo[2-one], 5-[13-fluorodibenz[b,e]olepin-11(8H)-ylidene]methyl-1,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



71-5 CAPLUS  
28-Benzimidazo[2-one], 5-[13-fluorodibenz[b,e]olepin-11(8H)-ylidene]methyl-1,3-dihydro-1-[2-(4-morpholinyl)propyl]- (CA INDEX NAME)



83-8 CAPLUS  
28-Benzimidazo[2-one], 5-[13,7-difluorodibenz[b,e]olepin-11(8H)-ylidene]methyl-1,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

granulomatosis, giant cell arthritis, rheumatoid arthritis, osteoarthritis, hay fever, allergic rhinitis, contact dermatitis, atopic dermatitis, exfoliative dermatitis, actinic keratosis, angioneurotic edema, chronic obstructive pulmonary disease, asthma, tendinitis, Bursitis, Crohn's disease, ulcerative colitis, autoimmune chronic active hepatitis, hepatitis, cirrhosis, inflammatory scalp alopecia, pemphigus, psoriasis, inflamed cysts, pyoderma gangrenosum, pemphigus vulgaris, bullous pemphigoid, dermatomyositis, eosinophilic fasciitis, erythema multiforme, inflammatory vasculitis, sarcoidosis, Sweet's disease, type 1 reactive leprosy, capillary hemangiomas, lichen planus, erythema nodosum, acne, hirsutism, toxic epidermal necrolysis, erythema multiforme, cutaneous T-cell lymphoma, mycoses, Alzheimer's disease, and multiple sclerosis. These dibenzosuberone deriv. II (R = H) were prep'd. with

yield via reaction of the corresponding sulfonyl chloride II (R = Cl) with

in THF. The prep'd. dibenzosuberone deriv. and analogs were

for muscarinic and glucocorticoid receptor binding.

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS


71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS


71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS

71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS 71-9 CAPLUS



RI 710346-12-6 CAPLUS  
 CH 26-Benzimidazol-2-one, 5-[(3-chlorodibenz[b,f][1,2,4]oxadiazol-5-yl)methyl]-, 2-ethylpyridin-1-yl- (6R)-  
 CA INDEX NAME)



OS..CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS  
 RECORD (14 CITINGS)  
 REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE EE  
 FORMAT

=> fil reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	14.28	216.46
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)		
	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.64	-1.64

FILE 'REGISTRY' ENTERED AT 13:32:04 ON 18 DEC 2009  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 16 DEC 2009 HIGHEST RN 1197964-91-2  
 DICTIONARY FILE UPDATES: 16 DEC 2009 HIGHEST RN 1197964-91-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.



Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
 predicted properties as well as tags indicating availability of  
 experimental property data in the original document. For information  
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10576761.str



chain nodes :

18 19 32 33 34

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 22 23 24 25 26 27 28 29  
30

chain bonds :

11-18 18-19 29-32 30-33 33-34

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-11 7-8 8-9 9-10 9-12 10-11 10-15 12-13  
13-14 14-15 22-23 22-27 22-28 23-24 23-30 24-25 25-26 26-27 28-29 29-30

exact/norm bonds :

5-7 6-11 7-8 8-9 10-11 11-18 18-19 22-23 22-27 22-28 23-24 23-30 24-25  
25-26 26-27 28-29 29-30 29-32 30-33 33-34

normalized bonds :



1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-12 10-15 12-13 13-14 14-15  
isolated ring systems :  
containing 1 :

G1:C,O

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS  
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 18:CLASS 19:CLASS  
22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS  
30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS

L7 STRUCTURE UPLOADED

=> d

L7 HAS NO ANSWERS

L7 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l7

SAMPLE SEARCH INITIATED 13:33:43 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 685 TO ITERATE

100.0% PROCESSED 685 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 12130 TO 15270

PROJECTED ANSWERS: 0 TO 0

L8 0 SEA SSS SAM L7

=> s l7 full

FULL SEARCH INITIATED 13:33:48 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 14347 TO ITERATE

100.0% PROCESSED 14347 ITERATIONS



0 ANSWERS

SEARCH TIME: 00.00.03

L9 0 SEA SSS FUL L7

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10576761.str



chain nodes :

18 19 32 33 34

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 22 23 24 25 26 27 28 29  
30

chain bonds :

11-18 18-19 29-32 30-33 33-34

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-11 7-8 8-9 9-10 9-12 10-11 10-15 12-13  
13-14 14-15 22-23 22-27 22-28 23-24 23-30 24-25 25-26 26-27 28-29 29-30

exact/norm bonds :

5-7 6-11 7-8 8-9 10-11 11-18 18-19 22-23 22-27 22-28 23-24 23-30 24-25  
25-26 26-27 28-29 29-30 29-32 30-33 33-34

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-12 10-15 12-13 13-14 14-15  
isolated ring systems :  
containing 1 :

G1:C,O

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS  
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 18:CLASS 19:CLASS  
22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS  
30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS

L10 STRUCTURE UPLOADED

=> d

L10 HAS NO ANSWERS

L10 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l19

L19 NOT FOUND

The L-number entered has not been defined in this session, or it  
has been deleted. To see the L-numbers currently defined in this  
session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l10

SAMPLE SEARCH INITIATED 13:35:46 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 4987 TO ITERATE

40.1% PROCESSED 2000 ITERATIONS

0 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 95505 TO 103975

PROJECTED ANSWERS: 0 TO 0

L11 0 SEA SSS SAM L10

=> s l19 full

L19 NOT FOUND

The L-number entered has not been defined in this session, or it  
has been deleted. To see the L-numbers currently defined in this  
session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l10 full

FULL SEARCH INITIATED 13:35:55 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 100911 TO ITERATE



100.0% PROCESSED 100911 ITERATIONS  
SEARCH TIME: 00.00.05

0 ANSWERS

L12 0 SEA SSS FUL L10

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10576761.str



chain nodes :

18 19 32 33 34

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 22 23 24 25 26 27 28 29  
30

chain bonds :

11-18 18-19 29-32 30-33 33-34

```

ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-11 7-8 8-9 9-10 9-12 10-11 10-15 12-13
13-14 14-15 22-23 22-27 22-28 23-24 23-30 24-25 25-26 26-27 28-29 29-30
exact/norm bonds :
5-7 6-11 7-8 8-9 10-11 11-18 18-19 22-23 22-27 22-28 23-24 23-30 24-25
25-26 26-27 28-29 29-30 29-32 30-33 33-34
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-12 10-15 12-13 13-14 14-15
isolated ring systems :
containing 1 :

```

G1:C,O

```

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 18:CLASS 19:CLASS
22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS
30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS

```

L13 STRUCTURE UPLOADED

=> d

L13 HAS NO ANSWERS

L13 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l13

SAMPLE SEARCH INITIATED 13:36:45 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 4987 TO ITERATE

40.1% PROCESSED 2000 ITERATIONS 1 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 95505 TO 103975

PROJECTED ANSWERS: 1 TO 143

L14 1 SEA SSS SAM L13

=> s l13 full

FULL SEARCH INITIATED 13:36:49 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 100911 TO ITERATE

100.0% PROCESSED 100911 ITERATIONS

83 ANSWERS

SEARCH TIME: 00.00.05

L15 83 SEA SSS FUL L13

=> d his

(FILE 'HOME' ENTERED AT 13:27:14 ON 18 DEC 2009)

FILE 'REGISTRY' ENTERED AT 13:27:32 ON 18 DEC 2009

L1           STRUCTURE UPLOADED  
L2           1 S L1  
L3           42 S L1 FULL  
L4           37 S L3 AND CAPLUS/LC  
L5           5 S L3 NOT L4

FILE 'CAPLUS' ENTERED AT 13:28:40 ON 18 DEC 2009

L6           2 S L4

FILE 'REGISTRY' ENTERED AT 13:32:04 ON 18 DEC 2009

L7           STRUCTURE UPLOADED  
L8           0 S L7  
L9           0 S L7 FULL  
L10          STRUCTURE UPLOADED  
L11          0 S L10  
L12          0 S L10 FULL  
L13          STRUCTURE UPLOADED  
L14          1 S L13  
L15          83 S L13 FULL

=> s l15 not l3

L16          43 L15 NOT L3

=> s l16 and caplus/lc

69529862 CAPLUS/LC

L17          31 L16 AND CAPLUS/LC


=> s l16 not l17

L18          12 L16 NOT L17

=> d l18 12

L18 ANWAKA 12 OF 12 REGISTRY COPYRIGHT 2009 ACS on STM  
 RE 040010-41-5 REGISTRY  
 ED Entered STM: 11 Aug 2005  
 CH ZR-Benzimidazol-2-one, 5-[(R)-[3,7-difluorodibenz[b,e]oxepin-11(6R)-  
 ylidene)methyl]-2-[(1S)-2-ethyl-3-pyrrolidinyl]-1,2-dihydro- (CA INDEX  
 NAME)  
 FE STEPLESSANCE  
 MF CHS RES TO RES QS  
 CI COM  
 SB CA

Absolute stereochemistry.  
 Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE "PROP" FORMAT\*\*

=> fil caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	567.92	784.38
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-1.64

FILE 'CAPLUS' ENTERED AT 13:37:20 ON 18 DEC 2009  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Dec 2009 VOL 151 ISS 26  
 FILE LAST UPDATED: 17 Dec 2009 (20091217/ED)  
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009  
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2009

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 13:27:14 ON 18 DEC 2009)

FILE 'REGISTRY' ENTERED AT 13:27:32 ON 18 DEC 2009

L1	STRUCTURE UPLOADED
L2	1 S L1
L3	42 S L1 FULL
L4	37 S L3 AND CAPLUS/LC
L5	5 S L3 NOT L4

FILE 'CAPLUS' ENTERED AT 13:28:40 ON 18 DEC 2009

L6	2 S L4
----	--------

FILE 'REGISTRY' ENTERED AT 13:32:04 ON 18 DEC 2009

L7	STRUCTURE UPLOADED
L8	0 S L7



```
L9          0 S L7 FULL
L10         STRUCTURE UPLOADED
L11         0 S L10
L12         0 S L10 FULL
L13         STRUCTURE UPLOADED
L14         1 S L13
L15         83 S L13 FULL
L16         43 S L15 NOT L3
L17         31 S L16 AND CAPLUS/LC
L18         12 S L16 NOT L17
```

FILE 'CAPLUS' ENTERED AT 13:37:20 ON 18 DEC 2009

=> s l17

```
L19         1 L17
```

=> d l19

119 APPENDIX 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STM

AB 0051438871 CAPLUS

20 1431133774

TI Preparation of triaryllic steroid hormone nuclear receptor modulators

TI Gaudinova, Zdenek;Gronow, Jonathan Edward; Jadhav, Prabhakar

TI Rongey, Matthew, Donald P.

IA Eli Lilly and Company, USA

SO PCT Int. Appl., 03 pp.

CODING: FIC002

ST Patient

LA English

PAR:STT 3

PATIENT NO.	KIND	DATA	APPLICATION NO.	DATA
FI	MO	2005054141	AI	20050721
W	AI	AG, AL, AM, AT, AD, AE, BA, BB, BC, BD, BE, BF, BG, BH, BI, BJ, BK, BL, BM, BN, BO, BP, BQ, BR, BS, BT, BU, BV, BW, BX, BY, BZ, CA, CB, CC, CD, CE, CF, CG, CH, CI, CJ, CK, CL, CM, CN, CO, CP, CQ, CR, CS, CT, CU, CV, CW, CX, CY, CZ, DA, DB, DC, DD, DE, DF, DG, DH, DI, DJ, DK, DL, DM, DN, DO, DP, DQ, DR, DS, DT, DU, DV, DW, DX, DY, DZ, EA, EB, EC, ED, EE, EF, EG, EH, EI, EJ, EK, EL, EM, EN, EO, EP, EQ, ER, ES, ET, EU, EV, EW, EX, EY, EZ, FA, FB, FC, FD, FE, FF, FG, FH, FI, FJ, FK, FL, FM, FN, FO, FP, FQ, FR, FS, FT, FU, FV, FW, FX, FY, FZ, GA, GB, GC, GD, GE, GF, GH, GI, GJ, GK, GL, GM, GN, GO, GP, GQ, GR, GS, GT, GU, GV, GW, GX, GY, GZ, HA, HB, HC, HD, HE, HF, HG, HH, HI, HJ, HK, HL, HM, HN, HO, HP, HQ, HR, HS, HT, HU, HV, HW, HX, HY, HZ, IA, IB, IC, ID, IE, IF, IG, IH, II, IJ, IK, IL, IM, IN, IO, IP, IQ, IR, IS, IT, IU, IV, IW, IX, IY, IZ, JA, JB, JC, JD, JE, JF, JG, JH, JI, JJ, JK, JL, JM, JN, JO, JP, JQ, JR, JS, JT, JU, JV, JW, JX, JY, JZ, KA, KB, KC, KD, KE, KF, KG, KH, KI, KJ, KK, KL, KM, KN, KO, KP, KQ, KR, KS, KT, KU, KV, KW, KX, KY, KZ, LA, LB, LC, LD, LE, LF, LG, LH, LI, LJ, LK, LM, LN, LO, LP, LQ, LR, LS, LT, LU, LV, LW, LX, LY, LZ, MA, MB, MC, MD, ME, MF, MG, MH, MI, MJ, MK, ML, MN, MO, MP, MQ, MR, MS, MT, MU, MV, MW, MX, MY, MZ, NA, NB, NC, ND, NE, NF, NG, NH, NI, NJ, NK, NL, NM, NO, NP, NQ, NR, NS, NT, NU, NV, NW, NX, NY, NZ, OA, OB, OC, OD, OE, OF, OG, OH, OI, OJ, OK, OL, OM, ON, OO, OP, OQ, OR, OS, OT, OU, OV, OW, OX, OY, OZ, PA, PB, PC, PD, PE, PF, PG, PH, PI, PJ, PK, PL, PM, PN, PO, PP, PQ, PR, PS, PT, PU, PV, PW, PX, PY, PZ, QA, QB, QC, QD, QE, QF, QG, QH, QI, QJ, QK, QL, QM, QN, QO, QP, QQ, QR, QS, QT, QU, QV, QW, QX, QY, QZ, RA, RB, RC, RD, RE, RF, RG, RH, RI, RJ, RK, RL, RM, RN, RO, RP, RQ, RR, RS, RT, RU, RV, RW, RX, RY, RZ, SA, SB, SC, SD, SE, SF, SG, SH, SI, SJ, SK, SL, SM, SN, SO, SP, SQ, SR, SS, ST, SU, SV, SW, SX, SY, SZ, TA, TB, TC, TD, TE, TF, TG, TH, TI, TJ, TK, TL, TM, TN, TO, TP, TQ, TR, TS, TU, TV, TW, TX, TY, TZ, UA, UB, UC, UD, UE, UF, UG, UH, UI, UJ, UK, UL, UM, UN, UO, UP, UQ, UR, US, UT, UV, UW, UX, UY, UZ, VA, VB, VC, VD, VE, VF, VG, VH, VI, VJ, VK, VL, VM, VN, VO, VP, VQ, VR, VS, VT, VU, VW, VX, VY, VZ, WA, WB, WC, WD, WE, WF, WG, WH, WI, WJ, WK, WL, WM, WN, WO, WP, WQ, WR, WS, WT, WU, WV, WW, WX, WY, WZ, XA, XB, XC, XD, XE, XF, XG, XH, XI, XJ, XK, XL, XM, XN, XO, XP, XQ, XR, XS, XT, XU, XV, XW, XX, XY, XZ, YA, YB, YC, YD, YE, YF, YG, YH, YI, YJ, YK, YL, YM, YN, YO, YP, YQ, YR, YS, YT, YU, YV, YW, YX, YY, YZ, ZA, ZB, ZC, ZD, ZE, ZF, ZG, ZH, ZI, ZJ, ZK, ZL, ZM, ZN, ZO, ZP, ZQ, ZR, ZS, ZT, ZU, ZV, ZW, ZX, ZY, ZZ		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LISTS DISPLAY FORMAT

OS COUNTRY 1431133774; INVPAT 1431133774

ORG.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

1.75

786.13

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-1.64

STN INTERNATIONAL LOGOFF AT 13:37:40 ON 18 DEC 2009